According to Barbara Wirostko, M.D., chief medical officer for Altheos, the question of whether a product candidate will be reimbursed by government and third-party payers is now surfacing in the earliest stages of discovery.
“Because there are now issues around who is going to reimburse and who is going to pay for novel, expensive new medications, there’s hesitancy on the R&D side to actually take risks and commit resources to a program unless there’s some assurance or insight into whether the emerging product will get reimbursed,” Dr. Wirostko says. “Companies need to have a solid commercial plan in place from the start, or they will be limited in their ability to run those early feasibility studies. And that commercial plan implies answering the question, ‘is this reimbursable, by whom…
Adam Bianchi. Chief Operating Officer, Cutting Edge Information, a research, consulting, and publishing firm focused on best-practice benchmarking for the pharmaceutical, biotech, medical device, and healthcare industries. For more information, visit cuttingedgeinfo.com.
Neil Bodick, M.D., Ph.D. Chief Medical Officer, Flexion Therapeutics, a specialty company developing novel drug treatments for large, underserved, and growing diseases. For more information, visit flexiontherapeutics.com.
Katherine Bowdish. President, Anaphore Inc., a company focused on a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. For more information, visit anaphore.com.
Chris Garabedian. President and CEO, AVI BioPharma Inc., a biopharmaceutical company focused on the discovery and development of novel RNA-based therapeutics. For more information, visit avibio.com.
Thomas Lawler. Senior Director, Clinical Project Management, AstraZeneca, a global biopharmaceutical company with a focus on the discovery, development, and commercialization of prescription medicines. For more information, visit astrazeneca-us.com.
Tim Rodell. President and CEO, GlobeImmune Inc., a biopharma company developing novel treatments for infectious diseases and cancer. For more information, visit globeimmune.com.
Douglas Williams, Ph.D. Executive VP, Research and Development, Biogen Idec, a biotech company that discovers and develops therapies for serious diseases, with a focus on neurology, immunology and hemophilia. For more information, visit biogenidec.com.
Barbara Wirostko, M.D. Chief Medical Officer, Altheos Inc., a biopharma company focused on the development of novel small-molecule drugs. For more information, visit altheos.net.